Notifications
Clear all
Topic starter
06/09/2026 6:20 pm
TL;DR: MCP servers are becoming the control layer between AI agents and life sciences systems, but LEVO argues that uncontrolled agent workflows create exposure across intellectual property, patient data, and regulatory compliance. The governance gap is that legacy IAM, perimeter security, and periodic compliance checks do not match real-time, tool-using AI behaviour.
NHIMG editorial — based on content published by LEVO: Runtime MCP Security for Life Sciences AI Workflows
Questions worth separating out
Q: How should teams govern AI agents that use MCP?
A: Treat each connected agent as a non-human identity with an owner, a scope, and a review cycle.
Q: Why do MCP workflows create regulatory risk for clinical and research systems?
A: Because the agent can move sensitive data across systems in real time, which makes jurisdiction, traceability, and approved-use checks harder to maintain.
Q: What breaks when AI agents are given broad standing access?
A: Broad standing access breaks governance because the agent can move from one task to another without a fresh authorization check.
Practitioner guidance
- Inventory every MCP-connected workflow Map each AI agent, tool, dataset, and regulated system involved in research, trial, and submission processes so the full access path is visible.
- Apply inline policy to high-risk data flows Block or redact sensitive compounds, trial records, and PHI at the moment the agent requests them, rather than relying on downstream review.
- Scope agent permissions to task boundaries Limit agent access to the minimum dataset, tool set, and jurisdiction needed for the current workflow, then revoke access when the task ends.
What's in the full article
LEVO's full article covers the operational detail this post intentionally leaves for the source:
- Runtime MCP security architecture for life sciences research and regulatory workflows
- Inline redaction and residency enforcement patterns for sensitive trial and compound data
- Kernel-level observability and audit evidence generation for compliance teams
- Operational examples of how AI agents interact with research databases and submission systems
👉 Read LEVO's analysis of runtime MCP security for life sciences AI workflows →
MCP servers in life sciences: what IAM teams need to watch?
Explore further
06/09/2026 6:21 pm
Runtime access, not static permissioning, is the governing problem for MCP in life sciences. MCP changes access from a fixed entitlement model to a live orchestration model where an agent can query, combine, and act across tools in a single session. That means the governance question is not whether the agent was authorised once, but whether every runtime action remained inside policy. The practical conclusion is that life sciences teams need to govern access at execution time, not only at provisioning time.
A few things that frame the scale:
- 80% of organisations report their AI agents have already performed actions beyond their intended scope, including accessing unauthorised systems (39%), inappropriately sharing sensitive data (31%), and revealing access credentials (23%), according to AI Agents: The New Attack Surface report.
- That same research says 92% agree governing AI agents is critical to enterprise security, yet only 44% have implemented any policies to do so.
A question worth separating out:
Q: How do security teams know if MCP runtime monitoring is actually working?
A: They should test whether one investigation can reconstruct the full chain from protocol request to host behaviour to agent decision. If the team still needs separate tools to explain file access, network egress, and tool sequencing, the observability model is incomplete. Effective monitoring produces one coherent attack story.
👉 Read our full editorial: Runtime MCP security for life sciences AI workflows
